S100A8 and glioma: Gielen et al. reported a tumor-grade-dependent increase in myeloid-derived suppressor cells (MDSCs) in glioma patients' blood based on the assessment of the presence and activation status of MDSCs in glioma patients' blood and tumor by measuring S100A8/9 and arginase levels [33].